2.所获成果(包括科研成果奖、专利、专著等)
(1)中华医学科技奖,医学科学技术奖三等奖,证书号:202003325P0504,我国汉族人群细胞色素P450遗传多态性及变异体的酶学活性研究 (2)北京市科学技术奖,自然科学二等奖,证书号:2020-Z04-2-02-D01,我国汉族人群药物代谢酶P450遗传多态性及变异体的酶学活性研究 (3)梁广;钱建畅;李丽;伍文奇;王怡;一种沙尔威酮衍生物在药物制备中的应用, 2021-10-22,发明专利, CN202011167212.0。 (4)郑小辉;钱建畅;赵云洁;刘志国;梁广;一种双羰基姜黄素衍生物及其应用, 2018-12-27,发明专利,ZL201811611318.8。 (5)钱建畅;胡国新;蔡剑平;陈冰冰;高楠勇;以CYP2D6基因型为依据的氟伏沙明临床精准应用虚拟仿真实验系统,发明专利, 202110462167.X。 |
3.发表论文(具有代表性的5篇) (1)Ren-ai Xu#, Qing-qing Li#, Nan-yong Gao, Jing Wang, Xin-yue Li, Feng Ye, Jin-huan Ni , Guo-xin Hu,*,Jian-chang Qian*. Effect of flavonoids and CYP3A4 variants on midostaurin metabolism.Food and Chemical Toxicology, 2023, 174: 113669. (2)Jianchang Qian#, *, Fei Zhuang#, Yujing Chen#, Xinrong Fan, Jun Wang, Zhe Wang, Yi Wang, Mingjiang Xu, Aleksandr V. Samorodov, Valentin N. Pavlov, Guang Liang*. Myeloid differential protein-2 inhibition improves diabetic cardiomyopathy via p38MAPK inhibition and AMPK pathway activation. BBA-Molecular Basis of Disease, 2022, 1868: 166369. (3)Nanyong Gao#, Xiaodan Zhang#, Xiaoqin Hu, Qihui Kong, JianPing Cai*, Guoxin Hu*,Jianchang Qian*. The influence of CYP3A4 genetic polymorphism and proton pump inhibitors on osimertinib metabolism. Frontiers in Pharmacology, 2022, 13:794931. (4)Xiaoqin Hu, Jinhuan Ni, Nanyong Gao, Zhize Ye, Guoxin Hu, Jianping Cai*,Jianchang Qian*. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline. Chemico-Biological Interactions, 2022, 366: 110123. (5)Jianchang Qian, Jianping Cai*, Guoxin Hu*. Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties.Expert Opinion on Drug Metabolism & Toxicology.2021, 2021,17(6):707-716. |